Debate: idiopathic short stature should be treated with growth hormone.

摘要: In this paper we outline the case for and against treatment of idiopathic short stature with growth hormone. Drs Ambler Fairchild argue that many those 'idiopathic' are not 'short, normal children' will ultimately receive molecular diagnoses. They also there is a subset children who suffer negative psychosocial consequences their whom hormone therapy effective. Growth has very good safety record likely to be as cost-effective in short-stature some other conditions currently funded. Dr Wilkinson counters associated physical or psychological illness, no evidence improves wellbeing. Moreover, represents form enhancement rather than treatment, fair use resources. Socially mediated disadvantage should treated by attention prejudice treatment.